ABOS (Acumen Pharmaceuticals) ROC (Joel Greenblatt) %: -35,760.00% (As of Mar. 2026)


ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.36
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals ROC (Joel Greenblatt) %?

Acumen Pharmaceuticals ABOS +6.79% 34 ROC (Joel Greenblatt) % is -35,760.00% as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,326 Biotechnology companies, Acumen Pharmaceuticals ranks worse than 96.23% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Acumen Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -35,760.00%.

The historical rank and industry rank for Acumen Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

ABOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -54400   Med: -28010.46   Max: -13399.74
Current: -37954.74

During the past 7 years, Acumen Pharmaceuticals's highest ROC (Joel Greenblatt) % was -13399.74%. The lowest was -54400.00%. And the median was -28010.46%.

ABOS's ROC (Joel Greenblatt) % is ranked worse than
96.23% of 1326 companies
in the Biotechnology industry
Industry Median: -297.95 vs ABOS: -37954.74

Acumen Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Acumen Pharmaceuticals  (NAS:ABOS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Acumen Pharmaceuticals ROC (Joel Greenblatt) % Related Terms


Acumen Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals ROC (Joel Greenblatt) % Chart

Acumen Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -54,400.00 -28,010.46 -13,399.74 -23,339.90 -40,244.33

Acumen Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31,205.62 -45,089.27 -32,594.54 -36,235.03 -35,760.00

ABOS vs QTTB, TNYA, MDWD: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Acumen Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acumen Pharmaceuticals ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's ROC (Joel Greenblatt) % falls into.


ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.762) - (16.846 + 0 + 4.246)
=-16.33

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.924) - (13.273 + 0 + 1.719)
=-11.068

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Acumen Pharmaceuticals for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-78.672/( ( (0.243 + max(-16.33, 0)) + (0.197 + max(-11.068, 0)) )/ 2 )
=-78.672/( ( 0.243 + 0.197 )/ 2 )
=-78.672/0.22
=-35,760.00 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -35,760.00% mean?
Acumen Pharmaceuticals (ABOS) has a ROC (Joel Greenblatt) % of -35,760.00% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Acumen Pharmaceuticals and its competitors. According to the industry distribution chart, Acumen Pharmaceuticals ranks #1276 out of 1326 companies in the Biotechnology industry, placing it in the top 96.2%.
Is Acumen Pharmaceuticals' ROC (Joel Greenblatt) % too high?
Acumen Pharmaceuticals' current ROC (Joel Greenblatt) % is -35,760.00%. Based on the distribution chart, Acumen Pharmaceuticals ranks #1276 out of 1326 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' ROC (Joel Greenblatt) % compare to QTTB and TNYA?
According to the Biotechnology industry distribution chart, Acumen Pharmaceuticals ranks #1276 out of 1326 companies for ROC (Joel Greenblatt) %. This places Acumen Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current ROC (Joel Greenblatt) % is -35,760.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current ROC (Joel Greenblatt) % of -35,760.00%. The current ROC (Joel Greenblatt) % is -35,760.00%. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current ROC (Joel Greenblatt) % is -35,760.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36
Price